The online version of this article (https://doi.org/10.1007/s00125-019-4877-2) contains peer-reviewed but unedited supplementary material, which is available to authorised users.
Rebeca Liébana-García and Oktawia Nilsson contributed equally to this study.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Finding new treatment alternatives for individuals with diabetes with severe insulin resistance is highly desired. To identify novel mechanisms that improve glucose uptake in skeletal muscle, independently from insulin levels and signalling, we have explored the therapeutic potential of a short peptide sequence, RG54, derived from apolipoprotein A-I (ApoA-I).
INS-1E rat clonal beta cells, C2C12 rat muscle myotubes and J774 mouse macrophages were used to study the impact of RG54 peptide on glucose-stimulated insulin secretion, glucose uptake and cholesterol efflux, respectively. GTTs were carried out on diet-induced insulin-resistant and Leprdb diabetic mouse models treated with RG54 peptide, and the impact of RG54 peptide on atherosclerosis was evaluated in Apoe−/− mice. Control mice received ApoA-I protein, liraglutide or NaCl.
The synthetic RG54 peptide induced glucose uptake in cultured muscle myotubes by a similar amount as insulin, and also primed pancreatic beta cells for improved glucose-stimulated insulin secretion. The findings were verified in diet-induced insulin-resistant and Leprdb diabetic mice, jointly confirming the physiological effect. The RG54 peptide also efficiently catalysed cholesterol efflux from macrophages and prevented the formation of atherosclerotic plaques in Apoe−/− mice.
The RG54 peptide exhibits good prospects for providing glucose control and reducing the risk of cardiovascular disease in individuals with severe insulin resistance.
ESM (PDF 517 kb)125_2019_4877_MOESM1_ESM.pdf
Forouzanfar MH, Alexander L, Anderson HR et al (2015) Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 386(10010):2287–2323. https://doi.org/10.1016/S0140-6736(15)00128-2 CrossRefPubMed
Siebel AL, Heywood SE, Kingwell BA (2015) HDL and glucose metabolism: current evidence and therapeutic potential. Front Pharmacol 6:258. https://doi.org/10.3389/fphar.2015.00258
Drew BG, Duffy SJ, Formosa MF et al (2009) High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation 119(15):2103–2111. https://doi.org/10.1161/CIRCULATIONAHA.108.843219 CrossRefPubMed
Lehti M, Donelan E, Abplanalp W et al (2013) High-density lipoprotein maintains skeletal muscle function by modulating cellular respiration in mice. Circulation 128(22):2364–2371. https://doi.org/10.1161/CIRCULATIONAHA.113.001551 CrossRefPubMedPubMedCentral
Domingo-Espin J, Lindahl M, Nilsson-Wolanin O, Cushman SW, Stenkula KG, Lagerstedt JO (2016) Dual actions of apolipoprotein A-I on glucose-stimulated insulin secretion and insulin-independent peripheral tissue glucose uptake lead to increased heart and skeletal muscle glucose disposal. Diabetes 65(7):1838–1848. https://doi.org/10.2337/db15-1493 CrossRefPubMed
Heywood SE, Richart AL, Henstridge DC et al (2017) High-density lipoprotein delivered after myocardial infarction increases cardiac glucose uptake and function in mice. Sci Transl Med 9(411). https://doi.org/10.1126/scitranslmed.aam6084 CrossRef
Petrlova J, Dalla-Riva J, Morgelin M et al (2014) Secondary structure changes in apoA-I Milano (R173C) are not accompanied by a decrease in protein stability or solubility. PLoS One 9(4):e96150. https://doi.org/10.1371/journal.pone.0096150 CrossRefPubMedPubMedCentral
Dalla-Riva J, Lagerstedt JO, Petrlova J (2015) Structural and functional analysis of the apolipoproteinA-I A164S variant. PLoS One 10(11):e0143915. https://doi.org/10.1371/journal.pone.0143915 CrossRef
Domingo-Espín J, Nilsson O, Bernfur K, Del Giudice R, Lagerstedt JO (2018) Site-specific glycations of apolipoprotein A-I lead to differentiated functional effects on lipid-binding and on glucose metabolism. Biochim Biophys Acta 1864(9):2822–2834. https://doi.org/10.1016/j.bbadis.2018.05.014 CrossRef
Gaspari T, Welungoda I, Widdop RE, Simpson RW, Dear AE (2013) The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE(-/-) mouse model. Diab Vasc Dis Res 10(4):353–360. https://doi.org/10.1177/1479164113481817 CrossRefPubMed
Bethel MA, Patel RA, Merrill P et al (2018) Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol 6(2):105–113. https://doi.org/10.1016/S2213-8587(17)30412-6 CrossRefPubMed
Miragoli M, Ceriotti P, Iafisco M et al (2018) Inhalation of peptide-loaded nanoparticles improves heart failure. Sci Transl Med 10(424). https://doi.org/10.1126/scitranslmed.aan6205 CrossRef
- ApoAI-derived peptide increases glucose tolerance and prevents formation of atherosclerosis in mice
Shelley J. Edmunds
Karin G. Stenkula
Jens O. Lagerstedt
- Springer Berlin Heidelberg
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
e.Med Kampagnen-Visual, Mail Icon II